EDIT today
$2.38-$0.13 (-4.99%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minBullish
5 minSymmetric Triangle
Daily trend turns up above $3.81
Key levels
Resistance$2.67
Resistance$2.41
Support$2.13
Support$1.82
Latest news & SEC filings
AnalystTwo brokerages repeat Buy calls on Editas Medicine
EarningsEditas Medicine posts smaller quarterly loss and higher revenue than expected
SEC FilingEditas Medicine, Inc. filed a report on a major company event (Form 8-K)
All EDIT news →About Editas Medicine
Editas Medicine is a gene editing company creating genomic medicines with CRISPR-based methods, employing both Cas9 and Cas12a proteins. Its lead preclinical candidate, EDIT-401, is an in vivo therapy intended to lower LDL cholesterol by boosting the LDL receptor. The company also works on in vivo editing of blood stem cells and other tissues via its lipid nanoparticle delivery system, and out-licenses its gene editing intellectual property to partners including Bristol Myers Squibb and Vertex Pharmaceuticals.
Based on the company's 10-K filed Mar 9, 2026.
Nasdaq · Healthcare
Editas Medicine, Inc. (EDIT)
What Is the Price Target for EDIT?
SEPT Low Target
$4.00
SEPT Mid Target
$5.00
SEPT High Target
$6.00
Analyst Consensus
$5.00
Is EDIT a Buy or Sell Right Now?
Thesis
- •Revenue growing 25.4% YoY with STRONG trend — consistent growth.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for EDIT.
Start Free Trial →Is EDIT Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$4.31
13
Moat Score
NONE
1/9
Piotroski Score
-13.2
Altman Z-Score
What Is Smart Money Doing with EDIT?
Insider Signal
SELLING
0 buys / 10 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Burkly Linda | officer | Buy | 16,533 | - | Nov 5, 2026 |
| O'Neill Gilmore Neil | director officer | Buy | 43,567 | - | Nov 5, 2026 |
| Parison Amy | officer | Sale | 453 | $1K | Sep 3, 2026 |
| Burkly Linda | officer | Sale | 709 | $2K | Sep 3, 2026 |
| O'Neill Gilmore Neil | director officer | Sale | 5,124 | $16K | Sep 3, 2026 |
| Parison Amy | officer | Sale | 678 | $2K | Aug 3, 2026 |
| Parison Amy | officer | Sale | 464 | $1K | Jun 3, 2026 |
| O'Neill Gilmore Neil | director officer | Sale | 15,380 | $42K | Jun 3, 2026 |
| Burkly Linda | officer | Sale | 731 | $2K | Jun 3, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →EDIT Growth Story
Revenue YoY
25.4%
3yr Revenue CAGR
27.1%
EPS Growth YoY
37.5%
FCF Growth YoY
24.3%
Revenue Trend
STRONG
Dark Pool Trades for EDIT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for EDIT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 12:23:26 | $2.38 | 37,989 | $$90K | SELL |
| 12:22:17 | $2.36 | 38,000 | $$90K | BUY |
| 22:26:05 | $2.41 | 5,000 | $$12K | SELL |
| 20:59:40 | $2.38 | 4,300 | $$10K | MIDPOINT |
| 20:59:40 | $2.38 | 1,000 | $$2K | MIDPOINT |
5 dark pool trades shown · $$205K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for EDIT
PREVIEWSEPT Investing provides real-time options flow tracking for EDIT, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $2.5 | Jan 15 | 65 | $$210 | 6 | SWEEP |
| CALL | $2.5 | Jan 15 | 65 | $$210 | 6 | SWEEP |
| CALL | $2.5 | Jan 15 | 65 | $$175 | 5 | SWEEP |
| CALL | $2.5 | Nov 20 | 9 | $$40 | 4 | SWEEP |
4 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Editas Medicine, Inc. (EDIT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →EDIT — frequently asked questions
What is EDIT stock price today?
Editas Medicine, Inc. (EDIT) is at $2.38, down 4.99% (-$0.13) at the Nov 11, 2026 close.
Why is EDIT stock moving today?
Latest EDIT news — Nov 11, 2026: Two brokerages repeat Buy calls on Editas Medicine · Nov 9, 2026: Editas Medicine posts smaller quarterly loss and higher revenue than expected
What is the EDIT price target?
The average analyst price target for EDIT is $5.00, ranging from $4 to $6, based on 3 analysts. Latest: Wells Fargo upgrade on Oct 8, 2026.
What do analysts rate EDIT?
Analyst ratings for EDIT: 2 Buy, 1 Hold, 0 Sell — consensus Buy.
Did EDIT beat earnings?
EDIT last reported on Nov 9, 2026: EPS -$0.15 vs -$0.18 expected — a beat of 16.7%.
Does EDIT pay a dividend?
EDIT does not currently pay a dividend.
What are EDIT support and resistance levels?
Support: $2.13, $1.82. Resistance: $2.41, $2.67, $3.00.
What are insiders doing with EDIT?
Insider activity: SELLING, 0 buys and 10 sells in the last 90 days.
What is the latest news on EDIT?
Nov 11, 2026: Two brokerages repeat Buy calls on Editas Medicine · Nov 9, 2026: Editas Medicine posts smaller quarterly loss and higher revenue than expected · Nov 9, 2026: Editas Medicine, Inc. filed a report on a major company event (Form 8-K)